Medication info

Rabeprazole Sodium Tablet 10 mg (Rabeprazole Sodium)

Prescription medicationExpired
Ingredient · strength
Rabeprazole Sodium›Strength being verified
Manufacturer / importer
Mirae Bio Pharmaceutical Co., Ltd.
Appearance
Light yellow round delayed-release film-coated tablet
Packaging
28 tablets (14 tablets/PTP packaging * 2) 28 tablets (14 tablets/AluAlu packaging * 2)
Approval status
Expired

MFDS item code 201307381 · Approved 2013.05.20

This product's status changed to Expired on 2023.05.20. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of gastroesophageal reflux disease, gastrointestinal ulcers, and Zollinger-Ellison syndrome
Who uses it
Adults · Children
Adult dosage
Gastric and duodenal ulcers: The usual dose for adults is 10 mg of rabeprazole sodium orally once daily. Depending on symptoms, 20 mg may be administered orally once daily. Treatment is usually given for up to 8 weeks for gastric ulcers and up to 6 weeks for duodenal ulcers. Erosive or ulcerative gastroesophageal reflux disease: Administer 10 mg or 20 mg once daily for 4 ∼ 8 weeks. If the condition has not healed after 8 weeks of treatment with a proton pump inhibitor (PPI), an additional 8 weeks of oral treatment with 10 mg or 20 mg twice daily may be given. However, the 20 mg twice-daily dose is only for patients with confirmed severe mucosal damage. Relief of symptoms of gastroesophageal reflux disease: Administer 10 mg once daily. If symptoms are not controlled after 4 weeks of treatment, further evaluation is required. After symptoms resolve, subsequent symptoms may be controlled, as needed, with on-demand treatment using 10 mg once daily. Long-term maintenance treatment of gastroesophageal reflux disease: Administer 10 mg or 20 mg orally once daily, depending on the patient. Helicobacter pylori eradication: Patients with Helicobacter pylori infection should receive eradication therapy. It is recommended that this medicine 20 mg, clarithromycin 500 mg, and amoxicillin 1 g be administered together twice daily for 7 days. Zollinger-Ellison syndrome: The recommended initial dose for adults is 60 mg once daily. The dose may be adjusted according to the individual patient's needs, up to 120 mg daily. Doses up to 100 mg may be administered once daily, while the 120 mg dose should be divided into 60 mg twice daily. Patients with Zollinger-Ellison syndrome have received this medicine for up to 1 year. ○ Patients with hepatic impairment Adverse reactions of hepatic encephalopathy have been reported in patients with cirrhosis. Therefore, administer with caution. ○ Older adults Administer with caution, as hepatic function is often impaired.
Children's dosage
Safety in children has not been established.

Ingredients

Manufacturer
Mirae Bio Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of gastroesophageal reflux disease, gastrointestinal ulcers, and Zollinger-Ellison syndrome

  • Gastric ulcer
  • duodenal ulcer
  • erosive gastroesophageal reflux disease
  • ulcerative gastroesophageal reflux disease
  • symptoms of gastroesophageal reflux disease
  • digestive ulcers infected with Helicobacter pylori
  • Zollinger-Ellison syndrome
View approved original text

This drug treats gastric ulcers and duodenal ulcers, and is also used for patients with erosive or ulcerative gastroesophageal reflux disease. It is effective for the alleviation of gastroesophageal reflux disease symptoms and long-term maintenance therapy. It may be prescribed in combination with antibiotics for patients with digestive ulcers infected with Helicobacter pylori. It is also used for the treatment of Zollinger-Ellison syndrome. This drug helps in the treatment and symptom improvement of various digestive diseases.

Dosage and Administration

Adult dosage

Gastric and duodenal ulcers: The usual dose for adults is 10 mg of rabeprazole sodium orally once daily. Depending on symptoms, 20 mg may be administered orally once daily. Treatment is usually given for up to 8 weeks for gastric ulcers and up to 6 weeks for duodenal ulcers. Erosive or ulcerative gastroesophageal reflux disease: Administer 10 mg or 20 mg once daily for 4 ∼ 8 weeks. If the condition has not healed after 8 weeks of treatment with a proton pump inhibitor (PPI), an additional 8 weeks of oral treatment with 10 mg or 20 mg twice daily may be given. However, the 20 mg twice-daily dose is only for patients with confirmed severe mucosal damage. Relief of symptoms of gastroesophageal reflux disease: Administer 10 mg once daily. If symptoms are not controlled after 4 weeks of treatment, further evaluation is required. After symptoms resolve, subsequent symptoms may be controlled, as needed, with on-demand treatment using 10 mg once daily. Long-term maintenance treatment of gastroesophageal reflux disease: Administer 10 mg or 20 mg orally once daily, depending on the patient. Helicobacter pylori eradication: Patients with Helicobacter pylori infection should receive eradication therapy. It is recommended that this medicine 20 mg, clarithromycin 500 mg, and amoxicillin 1 g be administered together twice daily for 7 days. Zollinger-Ellison syndrome: The recommended initial dose for adults is 60 mg once daily. The dose may be adjusted according to the individual patient's needs, up to 120 mg daily. Doses up to 100 mg may be administered once daily, while the 120 mg dose should be divided into 60 mg twice daily. Patients with Zollinger-Ellison syndrome have received this medicine for up to 1 year. ○ Patients with hepatic impairment Adverse reactions of hepatic encephalopathy have been reported in patients with cirrhosis. Therefore, administer with caution. ○ Older adults Administer with caution, as hepatic function is often impaired.

Children's dosage

Safety in children has not been established.

Precautions

This drug should not be used in patients who have had allergic reactions to specific ingredients or benzimidazole derivatives. Caution is required in cases of hypersensitivity to penicillin-based antibiotics or macrolide antibiotics, especially when combined with treatment for Helicobacter pylori eradication. Patients taking certain cardiac-related medications or antivirals should be careful as side effects may occur when co-administered with these medications. Pregnant or breastfeeding women should not take this drug. Patients with impaired liver function or elderly patients should be particularly careful when administering this drug, and caution is also needed in those with a history of allergies. This drug contains Yellow No. 4 (Tartrazine), so patients who are sensitive to it should be careful. If allergic symptoms such as rash, urticaria, or itching occur during treatment, discontinue use immediately. Regular blood tests and liver function tests are recommended due to possible changes in blood cell counts or liver function abnormalities. Symptoms related to cardiac issues, digestive system problems, or neurological symptoms may occur, and if symptoms develop, consult medical personnel. Long-term use may increase the risk of side effects such as osteoporosis or hypomagnesemia, so regular monitoring is required. This drug reduces gastric acid secretion, which can lead to bacterial overgrowth in the stomach; therefore, inform medical personnel if diarrhea persists. Caution is needed when driving or operating machinery as drowsiness or dizziness may occur. There may be potential interactions with other medications, so if you are taking other medications, be sure to inform medical personnel. There is no specific antidote for overdose, so appropriate treatment based on symptoms is necessary. This drug should not be chewed or crushed, and should be swallowed whole, keeping it out of reach of children. When taken for a long time, it is safest to use the minimum dose while receiving regular check-ups according to a doctor's instructions.

Side effects

Rash, hives, itching, erythrocytopenia, leukopenia, leukocytosis, eosinophilia, neutrophilia, lymphocytopenia, anemia, petechiae, lymphadenopathy, hypochromic anemia, pancytopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, elevated ALT, elevated AST, elevated ALP, elevated γ-GTP, elevated LDH, elevated total bilirubin, fulminant hepatitis, liver dysfunction, jaundice, hypertension, myocardial infarction, abnormal electrocardiogram, migraine, syncope, angina pectoris, heart block, palpitations, bradycardia, tachycardia, pulmonary embolism, ventricular tachycardia, thrombophlebitis, vasodilation, prolonged QTc, ventricular arrhythmia, diarrhea, constipation, abdominal pain, abdominal distension, dyspepsia, belching, nausea, rectal bleeding, bloody stool, anorexia, cholelithiasis, oral ulcer, dysphagia, gingivitis, cholecystitis, increased appetite, abnormal stools, colitis, esophagitis, glossitis, pancreatitis, proctitis, thirst, vomiting, lower abdominal pain, gastric body, gastritis, stomatitis, dysgeusia, hemorrhagic diarrhea, cholangitis, duodenitis, gastrointestinal bleeding, hepatic encephalopathy, hepatitis, liver cancer, hepatic steatosis, salivary gland enlargement, thirst, headache, insomnia, anxiety, dizziness, seizures, abnormal dreams, decreased libido, neuropathy, sensory disturbances, tremors, weakness, neuroexcitation, drowsiness, vertigo, depression, agitation, amnesia, confusion, extrapyramidal syndrome, increased circulatory blood volume, proximal muscle weakness, sensory impairment, reduced grip strength, language confusion, staggering, delirium, disorientation, hypersomnia, cough, pharyngitis, rhinitis, respiratory distress, asthma, nosebleed, laryngitis, hiccups, hyperventilation, bronchitis, sinusitis, apnea, respiratory depression, interstitial pneumonia, myalgia, back pain, arthritis, leg cramps, bone pain, arthropathy, bursitis, hypertonia, neuralgia, single contraction, sweating, alopecia, skin dryness, shingles, psoriasis, skin color changes, toxic epidermal necrolysis, mucous membrane syndrome, erythema multiforme, cataract, amblyopia, glaucoma, dry eyes, abnormal vision, tinnitus, otitis media, corneal opacity, blurriness, diplopia, hearing loss, eye pain, retinal degeneration, strabismus, proteinuria, cystitis, increased urination, dysmenorrhea, urinary difficulty, kidney stones, uterine bleeding, polyuria, gynecomastia, elevated thyroid-stimulating hormone, fractures, Clostridium difficile-associated diarrhea, systemic lupus erythematosus, discoid lupus erythematosus

Not everyone experiences these, and they can vary from person to person.

Storage

This drug must be stored in a tightly sealed container to prevent air and moisture ingress, and it is important to maintain a storage temperature between 1 degree and 30 degrees Celsius at room temperature. Storing in this manner helps to maintain the drug's effectiveness.

Appearance and packaging

Appearance

Light yellow round delayed-release film-coated tablet

Package unit

28 tablets (14 tablets/PTP packaging * 2) 28 tablets (14 tablets/AluAlu packaging * 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.